328918-93-0

Basic information

• Product Name: 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide
• Synonyms: 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide
• CAS NO: 328918-93-0
• Molecular Weight: 268.11
• Mol File: 328918-93-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide(328918-93-0)
• EPA Substance Registry System: 2-(3-Bromophenyl)-4,5-dimethyloxazole-3-oxide(328918-93-0)

Safety Data

• Hazardous Substances Data: 328918-93-0(Hazardous Substances Data)

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 135636-66-7 butane-2,3-dione mono-oxime 
• 57-71-6 2,3-Butanedione monoxime 

Downstream Products

• 853260-44-3 3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-(4-tert-butyl-phenoxy)-2-methyl-propionic acid ethyl ester 
• 853260-37-4 3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-p-tolyloxy-propionic acid ethyl ester 
• 328919-25-1 2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethanol 
• 328918-95-2 2-(3-Bromophenyl)-5-methyl-4-oxazoleacetic acid 
• 328918-97-4 2-[2-(3-bromophenyl)-5-methyl-oxazol-4-yl]ethanol 
• 328918-96-3 [2-(3-Bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 
• 853260-14-7 3-{4-[2-(2-biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ethyl ester 
• 328919-26-2 toluene-4-sulfonic acid 2-(2-biphenyl-3-yl-5-methyloxazol-4-yl)ethyl ester 
• 328918-94-1 2-(3-bromophenyl)-4-(chloromethyl)-5-methyloxazole 

Relevant articles and documents

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b